Physician profile
John Robert Dunn
NPI 1962687384
$1,085.28
in general payments reported to CMS, 2019-2025
21 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.99 · 2020: $109 · 2021: $186 · 2022: $72.00 · 2023: $365 · 2024: $85.59 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $683.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $188.47 | 2020-2025 | Farxiga |
| Dexcom, INC. | $136.50 | 2023-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $103.36 | 2020-2023 | Jardiance |
| Vanda Pharmaceuticals INC. | $101.67 | 2025 | Hetlioz, Fanapt |
| Novo Nordisk INC | $73.71 | 2019-2025 | Rybelsus, Wegovy |
| Abbvie INC. | $66.43 | 2020-2023 | Vraylar |
| Novartis Pharmaceuticals Corporation | $61.36 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.60 | 2025 | Caplyta |
| Inari Medical, INC. | $38.68 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Nabriva Therapeutics, Plc | $32.86 | 2021 | |
| Edwards Lifesciences Corporation | $31.61 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Glaxosmithkline, LLC. | $25.76 | 2020-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $24.93 | 2020 | |
| Pulmonx Corporation | $23.64 | 2024 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Abbott Laboratories | $23.10 | 2023 | Octrode |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $22.40 | 2025 | Rexulti |
| Neuraxis, INC. | $21.21 | 2024 | |
| Daiichi Sankyo INC. | $19.25 | 2023 | Injectafer |
| Allergan, INC. | $15.06 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.90 | 2023 | Strensiq |
| Sanofi-Aventis U.S. LLC | $12.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.